GILD Jan 2025 82.500 put
| Previous Close | 12.15 |
| Open | 12.15 |
| Bid | 11.10 |
| Ask | 12.10 |
| Strike | 82.50 |
| Expire Date | 2025-01-17 |
| Day's Range | 12.15 - 12.15 |
| Contract Range | N/A |
| Volume | |
| Open Interest | 1.19k |
- Reuters
US FDA mandates label updates on CAR-T cancer therapies
The U.S. Food and Drug Administration said on Thursday cancer therapies that use CAR-T technology will require changes to the so-called "boxed warning" to highlight the serious risk of T-cell blood cancer in patients who use these therapies. The health regulor has required related updates to other sections of the label such as warnings and precautions, postmarketing experience, patient counseling information and medication guide. In January, the FDA asked a host of drugmakers including Gilead Sciences, Johnson & Johnson and Novartis to add a boxed warning to their CAR-T cancer therapies, as it received reports of patients developing a type of T-cell blood cancer after being treated with them.
ZacksGilead Sciences (GILD) Sees a More Significant Dip Than Broader Market: Some Facts to Know
Gilead Sciences (GILD) closed at $66.16 in the latest trading session, marking a -1.15% move from the prior day.
ACCESSWIREGilead Sciences Publishes 2023 ESG Impact Report
NORTHAMPTON, MA / ACCESSWIRE / April 18, 2024 / Gilead Sciences published its 2023 Environmental, Social and Governance (ESG) Impact Report, which uses the ESG framework to highlight the successes and achievements of the prior year. In this year's ...
